In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited antiproliferative effects.
Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses / Ferolla, P., Faggiano, A., Grimaldi, F., Ferone, D., Scarpelli, G., Ramundo, V., Severino, R., Bellucci, M.C., Camera, L.M., Lombardi, G., Angeletti, G., Colao, A.. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - 35:3(2012), pp. 326-331. [10.3275/7869]
Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses
Faggiano, A;Ramundo, V;
2012
Abstract
In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited antiproliferative effects.| File | Dimensione | Formato | |
|---|---|---|---|
|
Ferolla_Long-acting-octreotide_2012.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
155.64 kB
Formato
Adobe PDF
|
155.64 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
